The CDC’s vaccine advisory committee is expected to vote on expanding access to RSV vaccines during the second session of its meeting.

Guidelines from the Advisory Committee on Immunization Practices (ACIP) inform clinician decision-making and influence insurance coverage determinations in the U.S.

Three RSV vaccines have been approved by the U.S. Food and Drug Administration: GSK’s Arexvy, Moderna’s mRESVIA, and Pfizer’s Abrysvo.

RSV is a common cause of lower respiratory tract infection and pneumonia, particularly in young children and older adults. An estimated 15,000–20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50–59 years, according to the CDC.

The panel was originally scheduled to meet in February, but the session was postponed to allow for public comment, according to the Department of Health and Human Services (HHS). The delay followed the appointment of Robert F. Kennedy Jr. as HHS Secretary.

ACIP members are expected to vote on whether to recommend a single dose of RSV vaccine for adults aged 50 to 59 years who are at increased risk for severe disease. Current CDC guidance recommends RSV vaccination for adults aged ≥75 years and for at-risk adults aged 60 to 74 years.

The CDC previously deferred issuing a recommendation for adults under age 60 in 2023.

GSK’s Arexvy and Pfizer’s Abrysvo are approved for adults aged 50–59 and 18–59 years, respectively, who are at increased risk for RSV-related lower respiratory tract disease. Moderna’s application for use in at-risk adults aged 18–59 is pending FDA review.

The panel will also vote on guidance for chikungunya and meningococcal vaccines.

ACIP discussed updates to COVID-19 booster recommendations for the 2024–2025 immunization season.